Publication: Association of histologic subtypes with genetic alteration and pd-l1 expression in pulmonary adenocarcinoma
Issued Date
2020-01-01
Resource Type
ISSN
20499469
20499450
20499450
Other identifier(s)
2-s2.0-85088528701
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Molecular and Clinical Oncology. Vol.13, No.3 (2020), 1-8
Suggested Citation
Bantita Phruttinarakorn, Thanyanan Reungwetwattana, Pimpin Incharoen Association of histologic subtypes with genetic alteration and pd-l1 expression in pulmonary adenocarcinoma. Molecular and Clinical Oncology. Vol.13, No.3 (2020), 1-8. doi:10.3892/mco.2020.2082 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/57744
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Association of histologic subtypes with genetic alteration and pd-l1 expression in pulmonary adenocarcinoma
Other Contributor(s)
Abstract
© 2020, Spandidos Publications. All rights reserved. Genetic alteration and programmed death-ligand 1 (PD-L1) expression have been revealed to be associated with various subtypes of pulmonary adenocarcinoma (ADC). The present study aimed to explore the association between histological subtypes and genetic alterations and PD-L1 expression. A total of 375 cases of pulmonary ADC were included. Genetic alterations were determined using next generation sequencing (NGS) in 136 cases. PD-L1 expression was detected by immunohistochemistry (based on clone 22C3) in the remaining 239 cases. Mutations in the epidermal growth factor receptor gene (EGFR) were detected in 76 (55.8%) cases associated with the papillary subtype (P=0.038). Mutations in the Kirsten rat sarcoma viral oncogene homolog gene (KRAS) were present in 46 (33.8%) cases associated with the lepidic subtype (P<0.001) and mucinous ADC (P=0.037). PD-L1 expression was identified in 63 (26.4%) cases associated with the solid subtype (P<0.001). In conclusion, the present study demonstrated that EGFR and KRAS mutations, alongside PD-L1 protein expression are significantly associated with specific subtypes of pulmonary ADC. These results should aid our ability to accurately select appropriate areas of the heterogeneous tumor for molecular testing methods and to predict patient outcomes and prognosis.